Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · Real-Time Price · USD
0.8100
+0.0100 (1.25%)
Apr 1, 2025, 10:41 AM EDT - Market open

Bone Biologics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
2.092.522.091.020.48
Upgrade
Research & Development
2.136.911.580.080.34
Upgrade
Operating Expenses
4.229.433.671.10.83
Upgrade
Operating Income
-4.22-9.43-3.67-1.1-0.83
Upgrade
Interest Expense
---0.73-0.81-1
Upgrade
Interest & Investment Income
0.060---
Upgrade
Other Non Operating Income (Expenses)
0.050.892.91--
Upgrade
EBT Excluding Unusual Items
-4.11-8.53-1.48-1.91-1.82
Upgrade
Legal Settlements
--0.41---
Upgrade
Other Unusual Items
---0.3-
Upgrade
Pretax Income
-4.11-8.95-1.48-1.61-1.82
Upgrade
Income Tax Expense
----0
Upgrade
Net Income
-4.11-8.95-1.48-1.61-1.82
Upgrade
Preferred Dividends & Other Adjustments
3.21----
Upgrade
Net Income to Common
-7.32-8.95-1.48-1.61-1.82
Upgrade
Shares Outstanding (Basic)
20000
Upgrade
Shares Outstanding (Diluted)
20000
Upgrade
Shares Change (YoY)
476.60%452.14%10.51%-15.67%-
Upgrade
EPS (Basic)
-4.83-34.01-31.15-37.35-35.68
Upgrade
EPS (Diluted)
-4.83-34.01-31.15-37.35-35.68
Upgrade
Free Cash Flow
-4.12-9.56-3.57-1.23-0.43
Upgrade
Free Cash Flow Per Share
-2.72-36.31-74.84-28.49-8.35
Upgrade
EBITDA
-----0.82
Upgrade
D&A For EBITDA
----0
Upgrade
EBIT
-4.22-9.43-3.67-1.1-0.83
Upgrade
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q